Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

ROCK inhibition in models of neurodegeneration and its potential for clinical translation.

Koch JC, Tatenhorst L, Roser AE, Saal KA, Tönges L, Lingor P.

Pharmacol Ther. 2018 Sep;189:1-21. doi: 10.1016/j.pharmthera.2018.03.008. Epub 2018 Apr 3. Review.

2.

Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma.

Raad M, El Tal T, Gul R, Mondello S, Zhang Z, Boustany RM, Guingab J, Wang KK, Kobeissy F.

Electrophoresis. 2012 Dec;33(24):3659-68. doi: 10.1002/elps.201200470. Epub 2012 Nov 26. Review.

PMID:
23161464
3.

ROCK in CNS: Different Roles of Isoforms and Therapeutic Target for Neurodegenerative Disorders.

Chong CM, Ai N, Lee SM.

Curr Drug Targets. 2017;18(4):455-462. doi: 10.2174/1389450117666160401123825. Review.

PMID:
27033194
4.

Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis.

Takata M, Tanaka H, Kimura M, Nagahara Y, Tanaka K, Kawasaki K, Seto M, Tsuruma K, Shimazawa M, Hara H.

Br J Pharmacol. 2013 Sep;170(2):341-51. doi: 10.1111/bph.12277.

5.

Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson's Disease and Amyotrophic Lateral Sclerosis.

Roser AE, Tönges L, Lingor P.

Front Aging Neurosci. 2017 Apr 4;9:94. doi: 10.3389/fnagi.2017.00094. eCollection 2017. Review.

6.

Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.

Raja SG.

Recent Pat Cardiovasc Drug Discov. 2012 Aug;7(2):100-4. Review.

PMID:
22670803
7.

Therapeutic potentials of the Rho kinase inhibitor Fasudil in experimental autoimmune encephalomyelitis and the related mechanisms.

Yan Y, Yu J, Gao Y, Kumar G, Guo M, Zhao Y, Fang Q, Zhang H, Yu J, Jiang Y, Zhang HT, Ma CG.

Metab Brain Dis. 2019 Apr;34(2):377-384. doi: 10.1007/s11011-018-0355-7. Epub 2018 Dec 14. Review.

PMID:
30552558
8.

Role of Rho Kinase Inhibition in the Protective Effect of Fasudil and Simvastatin Against 3-Nitropropionic Acid-Induced Striatal Neurodegeneration and Mitochondrial Dysfunction in Rats.

Ahmed LA, Darwish HA, Abdelsalam RM, Amin HA.

Mol Neurobiol. 2016 Aug;53(6):3927-3938. doi: 10.1007/s12035-015-9303-2. Epub 2015 Jul 15.

PMID:
26169112
9.

The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.

Eira J, Silva CS, Sousa MM, Liz MA.

Prog Neurobiol. 2016 Jun;141:61-82. doi: 10.1016/j.pneurobio.2016.04.007. Epub 2016 Apr 16. Review.

PMID:
27095262
10.

Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Hahmann C, Schroeter T.

Cell Mol Life Sci. 2010 Jan;67(2):171-7. doi: 10.1007/s00018-009-0189-x. Epub 2009 Nov 12. Review.

PMID:
19907920
11.

Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis.

Tönges L, Günther R, Suhr M, Jansen J, Balck A, Saal KA, Barski E, Nientied T, Götz AA, Koch JC, Mueller BK, Weishaupt JH, Sereda MW, Hanisch UK, Bähr M, Lingor P.

Glia. 2014 Feb;62(2):217-32. doi: 10.1002/glia.22601. Epub 2013 Dec 6.

PMID:
24311453
12.

FSD-C10: A more promising novel ROCK inhibitor than Fasudil for treatment of CNS autoimmunity.

Xin YL, Yu JZ, Yang XW, Liu CY, Li YH, Feng L, Chai Z, Yang WF, Wang Q, Jiang WJ, Zhang GX, Xiao BG, Ma CG.

Biosci Rep. 2015 Jul 29;35(5). pii: e00247. doi: 10.1042/BSR20150032.

13.

Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.

Feng Y, LoGrasso PV, Defert O, Li R.

J Med Chem. 2016 Mar 24;59(6):2269-300. doi: 10.1021/acs.jmedchem.5b00683. Epub 2015 Oct 30. Review.

PMID:
26486225
14.

Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease.

Tönges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego ÉM, Bähr M, Weishaupt JH, Lingor P.

Brain. 2012 Nov;135(Pt 11):3355-70. doi: 10.1093/brain/aws254. Epub 2012 Oct 19.

15.

Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders?

Chen M, Liu A, Ouyang Y, Huang Y, Chao X, Pi R.

Expert Opin Investig Drugs. 2013 Apr;22(4):537-50. doi: 10.1517/13543784.2013.778242. Epub 2013 Mar 5. Review.

PMID:
23461757
16.

Cellular pathways leading to neuronal dysfunction and degeneration.

Kazantsev AG.

Drug News Perspect. 2007 Oct;20(8):501-9. Review.

PMID:
18080037
17.

Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.

Tatenhorst L, Eckermann K, Dambeck V, Fonseca-Ornelas L, Walle H, Lopes da Fonseca T, Koch JC, Becker S, Tönges L, Bähr M, Outeiro TF, Zweckstetter M, Lingor P.

Acta Neuropathol Commun. 2016 Apr 22;4:39. doi: 10.1186/s40478-016-0310-y.

18.

Could pharmacological curtailment of the RhoA/Rho-kinase pathway reverse the endothelial barrier dysfunction associated with Ebola virus infection?

Eisa-Beygi S, Wen XY.

Antiviral Res. 2015 Feb;114:53-6. doi: 10.1016/j.antiviral.2014.12.005. Epub 2014 Dec 13. Review.

PMID:
25512227
19.

Targeting protein aggregation in neurodegeneration--lessons from polyglutamine disorders.

Weydt P, La Spada AR.

Expert Opin Ther Targets. 2006 Aug;10(4):505-13. Review.

PMID:
16848688
20.

Autophagy and apoptosis dysfunction in neurodegenerative disorders.

Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, Christoffersson J, Chaabane W, Moghadam AR, Kashani HH, Hashemi M, Owji AA, Łos MJ.

Prog Neurobiol. 2014 Jan;112:24-49. doi: 10.1016/j.pneurobio.2013.10.004. Epub 2013 Nov 6. Review.

Supplemental Content

Support Center